Galapagos

Beleggen in aandelen beurs Brussel, BEL 20, lokale fondsen, etc.
Plaats reactie
believer
Forum veteraan
Forum veteraan
Berichten: 1554
Lid geworden op: 14 Jan 2015 17:30
Likes: 802
Contact:

Re: Galapagos

Berichtdoor believer » 08 Jan 2018 19:46

Edit Fibrosis out of our RNA
DEALS & FINANCE
Clara Rodríguez Fernández Clara Rodríguez Fernández on 08/01/2018

Galapagos and ProQR will work together to target fibrosis using a technology to treat genetic diseases without permanent changes to the DNA.

A new research collaboration between two biotech companies in Leiden, the Netherlands, will aim to discover a new class of drugs to treat fibrosis — a process of excessive scarring that leads to a wide range of diseases. Galapagos, one of the largest biotech companies in Europe, will select the targets, while ProQR will use its RNA platform to discover drug candidates.

The team is searching for drugs called Axiomer Editing Oligonucleotides (EONs). These are short RNA sequences designed to selectively bind RNA molecules with a specific mutation. The EONs recruit a natural RNA editing machinery called ADAR to exchange an adenoside (A) nucleotide for an inosine, which is equivalent to guanosine (G).

ADVERTISEMENT


ProQR estimates that A to I changes could address over 20,000 mutations causing disease, most of them currently without treatment. And, since the edition happens in the RNA molecule, after it’s been copied from the DNA, the therapy affects the production of mutated proteins without making permanently changes to our genetic code.

Galapagos has a big pipeline, including several drugs for fibrotic diseases such as cystic fibrosis and idiopathic pulmonary fibrosis (IPF), but it’s mostly small drugs and some antibodies. With this new partnership, the company is expanding to newer technologies to fight these complex diseases. For ProQR, partnering with such a big player is surely great, especially now that it’s starting to recover from a historic low in its stock.

Images via Maxi_m/Shutterstock; ProQR

Read more on:Fibrosis,Galapagos,Netherlands,ProQR,RNA


Newsletter Subscription
Get the hottest European Biotech News in your inbox every Friday
jack. liked last!


vlere
Forum verkenner
Forum verkenner
Berichten: 39
Lid geworden op: 06 Mar 2017 16:04
Likes: 3
Contact:

Re: Galapagos

Berichtdoor vlere » 08 Jan 2018 20:45

2de aandeel in die sector!
Spijtig van de volgorde! Had liever eerst Galapagos gehad en dan ablynx.
Die nemen hun winst en proberen hier te verzilveren nu.

Ook wel goed voor ons maar toch liever 2 maal aan de kassa gepasseerd of ben ik de enige die er zo over denkt?

Gebruikersavatar
Lotus
Forum elite
Forum elite
Berichten: 2180
Lid geworden op: 22 Mei 2013 14:58
Likes: 355
Contact:

Re: Galapagos

Berichtdoor Lotus » 08 Jan 2018 21:52

Sirlander schreef:ik zie dat er bij de sluiting van de beurs nog enorm volume werd verhandeld...
zullen we het effect hier pas morgen bij de pre opening zien?

In de slotveiling kunnen allerlei orders worden afgewikkeld dat zegt weinig of niks over de koers van morgen.
Sirlander liked last!

Gebruikersavatar
Lama Daila
Forum actieveling
Forum actieveling
Berichten: 409
Lid geworden op: 20 Jul 2017 10:53
Likes: 438
Contact:

Re: Galapagos

Berichtdoor Lama Daila » 08 Jan 2018 22:17

jack. liked last!

Gebruikersavatar
Lama Daila
Forum actieveling
Forum actieveling
Berichten: 409
Lid geworden op: 20 Jul 2017 10:53
Likes: 438
Contact:

Re: Galapagos

Berichtdoor Lama Daila » 09 Jan 2018 06:35

https://globenewswire.com/news-release/ ... ology.html

ProQR and Galapagos Announce Research Collaboration on Fibrosis Targets Using ProQR’s Axiomer® technology


January 08, 2018 07:00 ET | Source: ProQR Therapeutics N.V.
LEIDEN, the Netherlands, Jan. 08, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), today announced that it has entered into a research collaboration agreement with Galapagos N.V. (Euronext & NASDAQ:GLPG). Under the agreement the two companies will work together to discover novel Axiomer Editing Oligonucleotides (EONs) against fibrosis targets selected by Galapagos. The targets that will be pursued in the collaboration and financial details about the collaboration are not disclosed.

ProQR is developing its RNA platform technology in areas of ophthalmology, cystic fibrosis and dystrophic epidermolysis bullosa. Through a collaboration with Amylon Therapeutics, the platform is also being developed for CNS indications including HCHWA-D. Recent progress in the validation and expansion of the platform included positive results in clinical trials in cystic fibrosis and the start of a clinical trial in Leber’s congenital amaurosis.

“In this collaboration we will explore a novel application of our Axiomer® technology to Galapagos’ fibrosis targets,” said Daniel A. de Boer, CEO of ProQR. “We look forward to working closely with the team at Galapagos. With their leadership in the discovery of novel drug targets and our platform technology and know-how, we can make a meaningful impact together.”

Onno van de Stolpe, CEO at Galapagos added: “With our vast experience in the discovery of novel drug targets, we believe ProQR’s Axiomer technology can be applied to strengthen the validation of novel targets from our platform. We look forward to collaborating with ProQR and its exciting RNA editing technologies.”
jack. liked last!

Gebruikersavatar
charel01
Premiummember
Premiummember
Berichten: 19876
Lid geworden op: 02 Jan 2012 20:17
Locatie: Zandhoven, Pulle
Likes: 6237
Contact:

Re: Galapagos

Berichtdoor charel01 » 09 Jan 2018 09:06

Op 8 januari 2018 hebben de analisten van InsingerGilissen hun beleggingsadvies voor Galapagos (GLPG; ISIN: BE0003818359) herhaald. Het advies van InsingerGilissen voor Galapagos blijft "aanbevolen".
De analisten behouden hun koersdoel van 100,00 EUR.
Soppi liked last!
Aandelenport: Geen zaken mee. Ik meld geen aan- en verkopen meer. Men vindt het toch altijd nodig om commentaar te leveren.

Sirlander
Forum verkenner
Forum verkenner
Berichten: 20
Lid geworden op: 05 Jan 2018 10:57
Likes: 3
Contact:

Re: Galapagos

Berichtdoor Sirlander » 09 Jan 2018 09:28

Ik begrijp niet waarom men niet springt op het aandeel van Galapagos.
Met of zonder overname dient dit een succes te zijn.
Hopelijk stilte voor de storm?

sparrow
Forum veteraan
Forum veteraan
Berichten: 1135
Lid geworden op: 05 Feb 2015 11:02
Likes: 301
Contact:

Re: Galapagos

Berichtdoor sparrow » 09 Jan 2018 10:03

Het wordt mooi in 'bedwang' gehouden precies.

pol
Forum verkenner
Forum verkenner
Berichten: 35
Lid geworden op: 07 Jul 2014 21:04
Likes: 11
Contact:

Re: Galapagos

Berichtdoor pol » 09 Jan 2018 10:47

Door wie of wat?

Sirlander
Forum verkenner
Forum verkenner
Berichten: 20
Lid geworden op: 05 Jan 2018 10:57
Likes: 3
Contact:

Re: Galapagos

Berichtdoor Sirlander » 09 Jan 2018 17:15

die amerikanen weten van meer...
believer liked last!